To identify the diagnostic and therapeutic approach (efficacy and toxicity) of patients with lymphoid malignant hemopathy who are managed in the hematology department.
Study Type
OBSERVATIONAL
Enrollment
13,000
Data collection for biostatistical analysis about hematological diseases
Hôpital Lyon Sud
Pierre-Bénite, France
RECRUITINGProgression-free survival
Period between the end of the first treatment and the first confirmed relapse of lymphoma of patients who have received treatment to treat their lymphoma.
Time frame: 730 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.